BioLargo to Present at the Growth Capital Expo 2014

SANTA ANA, CA--(Marketwired - Apr 24, 2014) - BioLargo, Inc. ( OTCQB : BLGO ) announced that Dennis Calvert, Chairman and CEO, is scheduled to present at the Growth Capital Expo on Wednesday, April 30th at 4:45 p.m. Pacific Time. The expo will take place at the Caesars Palace in Las Vegas, NV.

The event will not be webcast; however, the company's most recent investor presentation will be available at the company's website at www.BioLargo.com.

About BioLargo, Inc.
BioLargo, Inc. ( OTCQB : BLGO ) makes life better by delivering technology-based products that help solve some of the world's most important problems that threaten water, food, agriculture, healthcare and energy. More information can be found about the company and its subsidiaries at  www.BioLargo.com. The subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases the Advanced Oxidation Systems, including its AOS Filter, a product in development specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. BioLargo also owns a 50% interest in the Isan System, which was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis Project. The subsidiary Odor-No-More Inc., features award-winning products serving the pet, equine, and consumer markets, including the Nature's Best Solution® and Deodorall® brands. (www.OdorNoMore.com). The subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com), focuses on advanced wound care management and is preparing to make FDA 510(k) applications in 2014.

Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K for the year ended December 31, 2012.